macro

Novartis keeps its sales growth outlook at 5% a year through 2031

Novartis expects constant-currency sales to grow 5% a year through 2031 and core margin above 40% by 2029, according to TradingView.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

According to TradingView, Novartis expects constant-currency sales to grow by about 5% a year through 2031. The company targets a core operating income margin above 40% by 2029.

The outlook rests on higher peak-sales guidance for its medicines and a broad development pipeline. The same factors, the report says, support mid-single-digit long-term growth.

why it matters

This is a long-term target rather than new reported results. TradingView notes the text is an AI-generated summary that may contain inaccuracies, so key figures should be checked against the original company document. Actual progress will depend on how pipeline drugs perform in the market.

market impact

Novartis shares: a steady long-term growth target supports investor interest in the company

tags

instruments

NOVN

sources

  1. NOVN: Raised brand outlook and pipeline support +5% cc sales CAGR through 2031 — TradingView, 19 November 2026 at 06:14 UTC
  2. NOVN: Higher brand potential and a deep pipeline underpin +5% cc sales CAGR through 2031 — TradingView, 19 November 2026 at 06:14 UTC
  3. NOVN: Raised brand forecasts and a deep pipeline underpin +5% cc sales CAGR guidance through 2031 — TradingView, 19 November 2026 at 06:12 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗